COVID-19 in two severe asthmatics receiving benralizumab: busting the eosinophilia myth
| Autor: | Katharina Marth, Marco Idzko, Wolfgang Pohl, Karin Patocka, Andreas Renner |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
Pulmonary and Respiratory Medicine
2019-20 coronavirus outbreak Coronavirus disease 2019 (COVID-19) business.industry Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) lcsh:R lcsh:Medicine respiratory system Eosinophil Benralizumab 3. Good health 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine medicine.anatomical_structure 030228 respiratory system chemistry Immunology Eosinophilic Research Letter medicine Eosinophilia 030212 general & internal medicine medicine.symptom business |
| Zdroj: | ERJ Open Research, Vol 6, Iss 4 (2020) ERJ Open Research article-version (AM) Accepted Manuscript |
| ISSN: | 2312-0541 |
| Popis: | Amidst the current pandemic there is only little clinical evidence regarding COVID-19 infections in asthma patients. Chinese data [1, 2] suggests that asthma patients might not be of an elevated risk of severe infections. A recent article by Carli et al. [3] hypothesises that asthma might even have a protective effect in COVID-19 infections. It is important to point out, that this is purely theoretical. Eosinophils from healthy probands have an antiviral activity against respiratory syncytial virus and influenza virus, but not eosinophils collected from asthma patients [4]. Eosinopenia, alongside lymphopenia has been seen in COVID-19 patients [2]. Both eosinopenia and lymphopenia are more common in in patients with COVID-19 pneumonitis compared to patients with non-COVID-19 viral pneumonitis [5]. Azkur et al. attribute this to an overwhelming type 1 response [6]. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|